Heart Failure Clinical Trial
— CD-NP/LVADOfficial title:
A Phase I Trial to Determine Safety and Efficacy of Chronic Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
Verified date | July 2017 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The worldwide use of left ventricular assist devices (LVAD), which is mechanical device to
improve hemodynamic function, has improved the outcomes of severe heart failure (HF) patients
leading to the continued annual increase in the number of LVAD implantations. However LVAD
support still results in major complications such as renal failure or gastrointestinal
bleeding. The investigators hypothesize that such major complications may be due to
endothelial dysfunction induced by the lack of pulsatility, which may be improved by an
innovative designer natriuretic peptide, CD-NP. They have demonstrated its favorable actions
in animal models as well as humans, and tested its safety in LVAD patients. They hypothesize
that CD-NP will have renal and endothelial protective actions through its receptor GC-A and
GC-B. Thus, the investigators will test their hypothesis with a highly translational approach
to examine CD-NP's role in endothelial and renal protection.
The aim is to determine safety and tolerability together with cGMP activating, neurohumoral
modulating and renovascular protective properties of chronic subcutaneous delivery of CD-NP
compared to placebo in stable LVAD patients for 3 days.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 1, 2020 |
Est. primary completion date | May 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Male and non-pregnant/post-menopausal/sterile females, ages 18-90, in end-stage HF with LVAD support who are stable in the healed stage at least 3 months from the LVAD implant (Destination therapy only) (the post-menopausal state is defined as the absence of menses for = 1 year or serum follicle-stimulating hormone = 20 IU/L; sterilization in the female is defined as bilateral tubal occlusion for = 6 months, bilateral oophorectomy, or complete hysterectomy) - Be willing to provide informed consent. - All cardiac medications must be at stable doses 4 weeks prior to enrollment. Exclusion Criteria: - Known allergy or other adverse reactions to exogenous natriuretic peptides (CD-NP or its components, nesiritide, other natriuretic peptides, or related compounds). - Women who are pregnant, or breast-feeding. - Having received nesiritide within 7 days prior to entry into the study. - Having received any investigational drug or device within 30 days prior to entry into the study. - Clinically unstable patients (e.g. mean blood pressure < 70 mmHg, ongoing requirement for vasopressors, or mechanical ventilation). - Recent hospitalization for decompensated HF or recent defibrillation for cardiac resuscitation within 30 days prior to randomization. - Patients with guarded prognosis who are unlikely to derive meaningful benefit from CD-NP. - Presence of cardiac lesions or comorbidities that may contraindicate the use of natriuretic peptides, such as clinically significant cardiac valvular stenosis, hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or uncorrected congenital heart disease that contraindicates the use of vasodilators. - Symptomatic carotid artery disease, known critical carotid stenosis, or stroke within the past 3 months - Requirement of pressors for maintenance of blood pressure. - Intra-aortic blood pump use. - Severe aortic or mitral stenosis or significant LV outflow tract obstruction. - Clinically significant renal artery stenosis > 50% - Baseline hemoglobin < 9.0 g/dl. - Serum sodium < 130 mEq/L, potassium < 3.6 mEq/L, or magnesium < 1.5 mEq/L. - Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at least 5 times the upper limit of normal or bilirubin at least 5 times the upper limit of normal - Creatinine clearance (CrCl) < 30 ml.min-1.1.73m-2, as calculated by Cockcroft-Gault formula(67) and adjusted for body surface area within 3 months or requirement for dialysis. - Written history of alcohol or drug abuse within the past 6 months. - Inability to communicate effectively with study personnel. - BMI >40 |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hypotension | To assess safety and tolerability (without symptomatic hypotension or mean blood pressure <70 mmHg) of chronic continuous subcutaneous infusion administration of CD-NP. | 2 weeks | |
Secondary | Pharmacokinetic Outcome Characterization | Area under the plasma concentration versus time curve (AUC) assessed by plasma CD-NP and cGMP | 2 weeks | |
Secondary | Renal Function | Estimated GFR from creatinine clearance and | 2 weeks | |
Secondary | Endothelial function | Measurement by Reactive Hyperemia-peripheral arterial tonometry (RHI) | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|
||
Completed |
NCT04549181 -
Problem-Solving for Rural Heart Failure Dyads
|
N/A |